Drug intelligence / Profile preview

MOv18-TR66 F(ab')2

Development stage: Preclinical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Intraperitoneal

Overview

MOv18-TR66 F(ab')2 is a bispecific antibody fragment designed to redirect human T lymphocytes to target human ovarian carcinoma cells. It functions by simultaneously binding to the T cell receptor complex on T cells and a cell-surface antigen expressed by ovarian carcinoma cells. This retargeting of the immune system aims to impede tumor growth and improve host survival in ovarian cancer.

Targets

FOLR1 (FRα)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on MOv18-TR66 F(ab')2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOv18-TR66 F(ab')2.

Explore the full profile